Good to great: The emergence of adjuvant therapy in urologic cancersJanuary 12th 2023
"We are...entering a new era for patients with urologic malignancies. Furthermore, we are expanding our reach and influence in patient care designed to improve outcomes," writes Michael S. Cookson, MD, MMHC.
Dr. Moyad on the history of vitamin D trials in urologyJanuary 9th 2023
“It was vitamin E and selenium in 2011-2012. There was a lot of hype about it. People were very excited. They lost their excitement in urology about it, but then along came vitamin D,” says Mark A. Moyad, MD, MPH.
How testosterone therapy use in men with prostate cancer has evolvedJanuary 5th 2023
Based on current studies and anecdotal evidence, many of today’s urologists think it’s relatively safe to administer testosterone replacement in hypogonadal men on active surveillance or in those who have been treated with prostatectomy or cryosurgery. But these men should be closely monitored, they stress.
Robotic prostatectomy without ventilator general anesthesia? SP transvesical prostatectomy is making it a realityDecember 22nd 2022
Patients can now undergo prostate surgery with epidural anesthesia and light sedation, known as twilight sleep, without the need for a ventilator general anesthesia.
Olaparib/abiraterone combo approved in European Union for mCRPCDecember 21st 2022
The European Commission based its approval on results from the phase 3 PROpel trial, which showed that adding olaparib to frontline abiraterone acetate and prednisone/prednisolone significantly improved radiographic progression-free survival in patients with mCRPC.
The Evolution of AR Pathway Inhibitors and Docetaxel Utilization in mCRPC Treatment and the Impact on CabazitaxelDecember 16th 2022
Neal Shore, MD, FACS, speculates on how the utilization of AR-pathway inhibitors and docetaxel in earlier lines of mCRPC treatment has also influenced treatment with cabazitaxel.
Factors for Consideration When Selecting Patients with mCRPC for Treatment With CabazitaxelDecember 16th 2022
Neal Shore, MD, FACS, explains the treatment regimen he would have chosen for the patient with mCRPC in the presented case, and what factors he uses to inform treatment decision-making.
Cabazitaxel for the Treatment of mCRPC: Data From the PROSELICA and FIRSTANA TrialsDecember 16th 2022
Neal Shore, MD, FACS, discusses data from the PROSELICA and FIRSTANA trials investigating cabazitaxel for the treatment of mCRPC, including a look at the post-hoc analyses of PROSELICA.
Available Treatment Options for Metastatic Castration-Resistant Prostate Cancer (mCRPC) After Docetaxel and AR-Targeted TherapyDecember 16th 2022
Dr Shore reviews the available treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC), visceral disease, and no actionable genomic alterations, who received prior treatment with docetaxel and AR-targeted therapy.
FDA delays decision on olaparib/abiraterone combo for mCRPCDecember 15th 2022
The application is supported by the phase 3 PROpel trial, which showed that adding olaparib to frontline abiraterone acetate and prednisone/prednisolone significantly improved radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer.